7 Reasons Why the New CDx Launch Model Will Work | Diaceutics

7 Reasons Why the New CDx Launch Model Will Work

July 19th, 2016

7-Reasons-CDx-Launch-Work

The companion diagnostic launch model is poised to become the go-to method of releasing targeted medications to the public. This approach will not only deepen public satisfaction and trust in your pharmaceutical company but also increase profit margins by targeting your research and development efforts. Here are the reasons why:

1. Simultaneous launches for companion diagnostics that are coupled with a therapeutic solution are a key factor in unlocking the full potential of a therapy that is highlighted by particular biomarkers.

2. Its simplicity lies in the integration of diagnostic and therapy. Kept apart, the launch process is too unwieldy and dense, but when combined it becomes streamlined, leaner and more targeted toward those unique populations that it is designed to benefit.

3. Better communication between the therapeutic and diagnostic silos ensures that each team is on the same page and has the same goals. It is crucial that the components of each are known and respected in order to provide a cohesive launch that benefits both sectors.

4. Cookie cutter is out and specialization is in. Gone are the days when a one-size-fits-all drug launch provided pharmaceutical companies with the numbers they hoped for—and needed—in order to realize their desired return on investment. Instead, targeted specialization in the form of companion diagnostics provides these companies with the results they were projecting.

5. Launches using companion diagnostics are unique. This aspect allows them to easily stand out from the crowd, particularly for that segment of the population that is going to benefit most from the development. Highlighting the inter-relationship between diagnostics and therapies provides a personalization that just cannot be developed fully when launches for therapies are not coupled with diagnostics.

6. Value propositions can be increased due to a reduction in both development costs and sample sizes. Companion diagnostics could also improve the potential of a drug that is floundering due to lack of a targeted response. This process could potentially increase both the market size for the drug and its profitability.

7. The ability to develop and release drugs in a timely manner so that a well-defined subset of the population can reap the benefits means that pharma companies see a much quicker return on their investment. In addition, the speed at which the drug can be released means that less time is spent on testing populations that might not be a match.

Utilizing the companion diagnostic launch process is a key element in the future success of pharma companies. Is your company ready?

Launch Planner Free Demo

Webinars & Podcasts

July 5th, 2019
Liquid Biopsy in NSCLC
August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Publications

June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications